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Mutations in PGAP3 Impair GPI-Anchor Maturation,
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Glycosylphophatidylinositol (GPI)-anchored proteins play important roles in many biological processes, and mutations affecting
proteins involved in the synthesis of the GPI anchor are reported to cause a wide spectrum of intellectual disabilities (IDs) with charac-
teristic additional phenotypic features. Here, we describe a total of five individuals (from three unrelated families) in whomwe identified
mutations in PGAP3, encoding a protein that is involved in GPI-anchor maturation. Three siblings in a consanguineous Pakistani family
presented with profound developmental delay, severe ID, no speech, psychomotor delay, and postnatal microcephaly. A combination of
autozygosity mapping and exome sequencing identified a 13.8 Mb region harboring a homozygous c.275G>A (p.Gly92Asp) variant in
PGAP3 region 17q11.2–q21.32. Subsequent testing showed elevated serum alkaline phosphatase (ALP), a GPI-anchored enzyme, in all
three affected children. In two unrelated individuals in a cohort with developmental delay, ID, and elevated ALP, we identified com-
pound-heterozygous variants c.439dupC (p.Leu147Profs*16) and c.914A>G (p.Asp305Gly) and homozygous variant c.314C>G
(p.Pro105Arg). The 1 bp duplication causes a frameshift and nonsense-mediated decay. Further evidence supporting pathogenicity of
themissensemutations c.275G>A, c.314C>G, and c.914A>Gwas provided by the absence of the variants from ethnicallymatched con-
trols, phylogenetic conservation, and functional studies on Chinese hamster ovary cell lines. Taken together with recent data on PGAP2,
these results confirm the importance of the later GPI-anchor remodelling steps for normal neuronal development. Impairment of PGAP3
causes a subtype of hyperphosphatasia with ID, a congenital disorder of glycosylation that is also referred to as Mabry syndrome.Glycosylphophatidylinositol (GPI) anchoring is a post-
translational modification that tethers proteins to plasma
membranes, and it is thought to play a role in protein sort-
ing and trafficking.1 The GPI anchor is well conserved
among eukaryotes, and there are over 150 mammalian
GPI-anchored proteins (GPI-APs), including receptors,
adhesion molecules, and enzymes.1 Many of these pro-
teins are critical for normal neural and embryonic develop-
ment.2,3 There are around 30 genes known to be involved
in the biosynthesis and remodelling of the GPI anchor,
which is formed in the endoplasmic reticulum (ER), where
it is attached by the GPI transamidase to a protein showing
a specific C-terminal signal before it is transported to
the Golgi apparatus for fatty acid remodelling and cellular
export.
In the last 4 years, germline mutations in eight genes
selectively involved in the GPI-anchor-synthesis pathway
have been shown to cause a wide phenotypic spectrum
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malformations and minor anomalies to nonsyndromic
forms. Congenital disorders that are caused by an impair-
ment of GPI-anchor synthesis and maturation are now
classified as congenital disorders of glycosylation (CDGs),
a diverse class of metabolic diseases.4
PIGV (MIM 610274), PIGO (MIM 614730), and PGAP2
(MIM 615187), three different genes in the GPI-anchor-
synthesis pathway, have been implicated in hyperphos-
phatasia with mental retardation syndrome (HPMRS
[MIM 239300]), also known asMabry syndrome, a recently
delineated autosomal-recessive form of ID with a distinct
facial dysmorphism, consistently elevated serum alkaline
phosphatase (ALP) (hyperphosphatasia), brachytelepha-
langy, and seizures. All individuals with congenital impair-
ment of GPI-anchor synthesis have residual surface levels
of GPI-anchored proteins, and it is hypothesized that
complete-loss-of-function mutations in genes involved
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The effect of mutations causing GPI-anchor deficiencies
can be subdivided into groups on the basis of the serum
activity of the marker enzyme ALP. Mutations in PIGA
(MIM 311770), PIGL (MIM 605947), PIGM (MIM
610273), PIGN (MIM 606097), and PIGT (MIM 610272)
affect early GPI-anchor synthesis and the attachment of
proteins to the GPI anchor.6–10 These variants result in
primary reduced surface levels of GPI-APs because of their
increased intracellular degradation and are not associated
with high serum ALP. Mutations in PIGV and PIGO affect
late GPI-anchor synthesis.11,12 However, GPI transamidase
recognizes the incomplete GPI anchor and cleaves the GPI
attachment signal, leading to the generation of non-GPI-
anchored soluble proteins.13 Individuals with mutations
in PIGV and PIGO have primary reduced GPI-AP surface
levels as a result of increased secretion into the extracel-
lular space, resulting in high serum ALP. Recently, muta-
tions in PGAP2 have been reported to affect the final
GPI-anchor fatty-acid-remodelling step and to thus
result in abnormal GPI-APs that are more prone to
cleavage.14–16 Individuals with PGAP2mutations have sec-
ondary reduced GPI-AP surface levels also as a result of
increased secretion into the extracellular space, resulting
in high serum ALP. GPI remodelling occurs in the Golgi
and involves the removal of an unsaturated fatty acid at
the sn-2 position by PGAP3 and its subsequent substitu-
tion with a saturated fatty acid by PGAP2. Fatty acid
remodelling is critical for proper association between
GPI-APs and lipid rafts.17
A number of deficient GPI-pathway genes were
first identified via traditional autozygosity mapping in
combination with next-generation sequencing methodol-
ogies.10,14 This methodology has become a key strategy
for the identification of disease-associated genes, particu-
larly those related to genetically heterogeneous conditions
such as ID, and was the approach taken for the first family
described here.18
Family A originates from the Sargodha district of Punjab
in Pakistan. The parents are second cousins, and all three
children (Figures 1A and 2A) presented with profound
developmental delay, severe learning disability, no speech,
psychomotor delay, and postnatal microcephaly (2 to3
SDs) at the ages of 17, 8, and 4 years. Further clinical details
are summarized in Table 1. After a ASPM test that did not
detect pathogenic variants, they were recruited into the
ongoing Structural Brain Abnormalities and Learning
Disabilities Study (see Oxford Brain Abnormality Research
Group in Web Resources), which received UK ethics
approval from the Wales Research Ethics Committee (12/
WA/0001) and obtained informed consent from the
responsible persons on behalf of all study participants.
Blood DNA samples for IV-2, IV-3, V-1, V-2, and V-3 were
run on CytoSNP12v2 arrays (Illumina), which confirmed
familial relationships and that there were no copy-number
changes of likely clinical relevance (Table S1, available on-
line). Autozygosity mapping was then used for identifying
a single 13.8 Mb candidate region in 17q11.2–q21.32The Americ(Figure S1). None of the 359 annotated genes appeared to
be obvious candidates, and so an exome sequencing
approach was adopted.
The exome of proband V-2 was enriched (TruSeq,
Illumina) and sequenced on a HiSeq2500 (Illumina) with
the use of standard settings and the 100 bp paired-end
read format. Reads were mapped to the human reference
sequence (UCSC Genome Browser, hg19) with the use of
Stampy,19 and variants were called with Platypus. The re-
sulting VCF file was uploaded into Ingenuity Variant Anal-
ysis (v.2.1.20130711) and filtered for rare variants that
were in the homozygous region on chromosome 17 and
predicted to be deleterious (Table S2 and Web Resources).
The single remaining variant was a c.275G>A change in
PGAP3 (RefSeq accession number NM_033419.3). Sanger
sequencing confirmed that this variant cosegregated with
disease, consistent with an autosomal-recessive mode of
inheritance (Figure 1B). The variant is predicted to cause
a p.Gly92Asp alteration to the protein sequence at a highly
conserved position (Figure 1C) and is not present at any
frequency in the NHLBI Exome Sequencing Project Exome
Variant Server (EVS), 1000 Genomes (version 3), or 274
in-house genomes of mixed ancestry. The mutation was
also not detected in 108 Punjabi individuals from Lahore,
suggesting that c.275G>A is unlikely to be a variant
specific to this ethnicity.
In parallel, we performed targeted sequencing in 19 indi-
viduals with ID and elevated ALP and in whom HPMRS
was suspected. The Charite´ University Medicine ethics
board approved this study, and we obtained informed con-
sent from the responsible persons (parents) on behalf of all
study participants. After excluding pathogenic PIGVmuta-
tions that are themost common cause of HPMRS by Sanger
sequencing, we subjected DNA to enrichment of all 30
known genes associated with GPI-anchor synthesis by
using a customized SureSelect library (Agilent), as well as
subsequent sequencing on a HiSeq2000, as previously
described.15 Sequence variants were filtered under an
autosomal-recessive model of inheritance in GeneTalk,20
which yielded potentially pathogenic variants in
PGAP3 in two individuals. Compound-heterozygous
variants c.439dupC (p.Leu147Profs*16) and c.914A>G
(p.Asp305Gly) were detected in individual II-1 from family
B, and homozygous variant c.314C>G (p.Pro105Arg) was
identified in individual II-1 from family C (Figure 1B).
The detailed clinical findings of individual II-1 from
family B were reported previously (affected individual 4
in Thompson et al.)21 together with a single rare heterozy-
gous variant in PIGV, c.1369C>T.21 However, in PIGV-
defective Chinese hamster ovary (CHO) cells, the altered
protein restored the surface levels of GPI-APs as efficiently
as the wild-type protein, suggesting no functional impair-
ment of PIGV (Figure S4). In contrast, the duplication
of c.439dupC in PGAP3 causes a frameshift that introduces
a premature stop codon, most likely resulting in nonsense-
mediated decay of the transcript. To exclude further candi-
date mutations, we exome sequenced DNAs of the affectedan Journal of Human Genetics 94, 278–287, February 6, 2014 279
Figure 1. Pedigrees, Sanger Validation, and Phylogenetic Conservation of the Variant Filtering Cascade andMolecular Characteriza-
tion of PGAP3 Mutations
(A) Pedigrees are shown for family A (of Pakistani descent), family B (of European descent), and family C (of Saudi Arabian origin).
Shading indicates ID and hyperphosphatasia, and proven heterozygote carriers are shown by a dot. In family A, the gray dotted lines
indicate an additional consanguineous loop that was not described in the clinical notes but that was inferred by the high inbreeding
coefficient detected in IV-2 from the SNP array data. The proband is indicated with an arrow.
(B) Sanger validation and segregation testing of PGAP3 variants. DNA for the unaffected double first cousins in family A (collectively
labeled as V-4) was not available.
(C) ClustalW alignment of amino acid sequence shows high evolutionary conservation.individual of family B and her parents and confirmed the
compound-heterozygous variants in PGAP3 as the only
candidate mutations for an autosomal-recessive model of
inheritance.22,23
Individual II-1 of family B is the first child of nonconsan-
guineous European-American parents (Table 1 and Figures
1A and 2B). Her psychomotor development was severely
delayed, and she developed tonic-clonic seizures. Physical
examination at the age of 10 years showed postnatal short
stature, dystrophy, normal occipitofrontal circumference
(OFC), and dysmorphic facial features. ALP levels were
repeatedly elevated, and a GPI-anchor deficiency on gran-
ulocytes andmonocytes could bemeasured by flow cytom-
etry with CD16, CD24, and fluorescence-labeled aerolysin
staining (Figure 3A). In family C, individual II-1 is the first
child of consanguineous parents of Saudi Arabian origin
(Table 1 and Figures 1A and 2C). She had severe psy-280 The American Journal of Human Genetics 94, 278–287, Februarychomotor delay. Myoclonic seizures started in her second
year of life. Physical examination of this 2-year-old female
showed normal growth parameters and OFC but axial
muscular hypotonia, uncoordinated movements, and
facial dysmorphism. ALP activity was elevated in repeated
tests. Sanger sequencing confirmed that the parents are
heterozygous for c.314C>G, and the mutation was not
detected in 52 Arabic controls or the NHLBI Exome
Sequencing Project EVS, suggesting that it might be a pri-
vate mutation specific to this family (Figure 1B).
The most common features noted in all affected individ-
uals were normal growth parameters and OFC at birth,
severe psychomotor delay with no speech and marked
motor delay, and characteristic facial features. Four were
unable to walk, whereas the other began to walk with sup-
port at the age of 3. Seizures starting between the ages of
18 months and 12 years developed in four of five affected6, 2014
Figure 2. Photographs of Affected Individuals
Facial features seen in (A) individual V-3 from family A, (B) individual II-1 from family B, and (C) individual II-1 from family C at the ages
of 4, 10, and 2 years, respectively. These individuals bear a striking resemblance with a broad nasal bridge, long-appearing palpebral
fissures, a broad nasal tip, a short nose, a long philtrum, a thin and wide upper lip, full cheeks, and large fleshy ear lobes.individuals. Three were described as having tonic-clonic
seizures, and the other had myoclonic seizures. Consistent
ALP elevation varied between 1.4 and 5 times the age-
adjusted upper limit of the normal range. The facial gestalt
was similar to that of individuals with HPMRS and
included features such as a broad nasal bridge, a short
nose with a broad nasal tip, a thin and wide upper lip,
and large fleshy ear lobes. In contrast, postnatal develop-
ment of head circumference and growth parameters
differed among the affected individuals studied here.
Affected individuals in family A developed microcephaly,
whereas OFC was in the mean range in the other individ-
uals. In the affected individual from family B, marked short
stature was present, whereas the other affected individuals
had a mean height according to age. Two of five individ-
uals had cleft palate, whereas abnormal MRI findings
such as thin corpus callosum and dilated lateral ventricles
were observed in the affected individual from family C.
The common features of all individuals reported with
mutations in PIGV, PIGO, PGAP2, and PGAP3 are severe
psychomotor delay and ID, epilepsy, elevated ALP, and a
distinctive facial gestalt. In contrast, brachytelephalangy,
which is an important diagnostic sign in other types of
HPMRS, is not present in any affected individuals with
PGAP3 mutations. Marked variability regarding the post-
natal growth andOFC has also been observed in the groups
of affected individuals carrying PIGV, PIGO, and PGAP2
mutations. Also, cleft palate has been previously docu-
mented in other individuals with HPMRS due tomutations
in these genes. In individuals affected by HPMRS and
mutations in genes other than PGAP3, associated mal-
formations seem to appear more frequently and their spec-
trum seems to be broader.
To determine the functional consequences of the four
PGAP3 mutations, we used a mutant CHO cell line defec-
tive in both PGAP3 and PGAP2 (see Figure S3 for principles
of the assay).17 The mutant cells have GPI-APs at mildlyThe Americreduced levels because of a lack of GPI fatty acid remodel-
ling. When wild-type PGAP3 cDNA was transfected, the
first step in the fatty acid remodelling was restored,
whereas the second step remained defective, leading to
the release of lyso-GPI intermediates and resulting in a
severe reduction in the surface levels of GPI-APs
(Figure 3Bi). If the mutant PGAP3 cDNA has decreased
activity, reduction in the surface GPI-AP levels would be
partial. Mutant PGAP3 cDNA bearing the mutation found
in family A (c.275G>A [p.Gly92Asp]) either did not reduce
or reduced only slightly the surface levels of three GPI-APs:
CD59, CD55 (DAF), and urokinase plasminogen activator
receptor (uPAR), indicating that the substitution caused a
null or nearly null phenotype (Figure 3Bii). One of the
substitutions found in family B (p.Leu147Profs*16) also
caused a null phenotype, whereas the other (p.Asp305Gly)
significantly reduced levels of all three GPI-APs, indicating
some residual activity (Figure 3Biii). The substitution
found in family C (p.Pro105Arg) caused less efficient
reduction of GPI-APs than did the p.Asp305Gly substitu-
tion in family B, indicating an even lower residual activity
(Figure 3Biv).
To clarify the mechanisms of these functional losses, we
expressed mutant PGAP3 clones that were hemagglutinin
(HA) tagged at the N terminus in CHO cells and analyzed
them by SDS-PAGE and immunoblotting (Figure 4) and
immunofluorescence microscopy (Figure 5) with anti-HA.
On SDS-PAGE and immunoblotting, HA-PGAP3 appeared
as a smear band at around 37–45 kDa and several clear
bands at around 23–35 kDa (Figure 4A, lane 3). After treat-
ment with PNGase F to remove N-glycan, the smear band
disappeared and a band at 33 kDa corresponding to de-
N-glycosylated full-size protein became a major one
(lane 1). The altered (p.Gly92Asp) protein in family A
showed similar profiles (lanes 7 and 9), suggesting
normal levels of PGAP3 bearing normally matured N-
glycan. Consistently, on immunofluorescence microscopy,an Journal of Human Genetics 94, 278–287, February 6, 2014 281
Table 1. Summary of Clinical Findings in Individuals with PGAP3 Mutations
Clinical Findingsa
Individual
V-1 (Family A) V-2 (Family A) V-3 (Family A) II-1 (Family B) II-1 (Family C)
Ethnicity Pakistani (Sargodha
district of Punjab)
Pakistani (Sargodha
district of Punjab)
Pakistani (Sargodha
district of Punjab)
American (European
descent)
Saudi-Arabian
Consanguinity yes yes yes no yes
Age of last assessment
(years)
17 8 4 10 2
OFC at birth normal normal normal normal normal
OFC 2 to 3 SDs 2 to 3 SDs 3 SDs mean mean
Height normal normal normal 4 SDs normal
Weight normal normal normal 2 SDs normal
Global developmental
delay (HP:0001263)
yes yes yes yes yes
Motor delay
(HP:0001270)
severe (unable
to walk)
severe (unable
to walk)
severe (unable
to walk)
severe (walk with
support at age of
3 years)
severe (unable
to walk)
Speech and language
development
none none none none none
Muscular hypotonia
(HP:0001252)
yes yes yes yes yes
Seizures (HP:0001250) yes yes no yes yes
Age of onset of seizures
(years)
12 4 NA 4 1.5
Type of seizures generalized
tonic-clonic
generalized
tonic-clonic
NA tonic-clonic and
cluster
myoclonic
Antiepileptic drugs valproate valproate NA rufinamide,
pregabaline
valproate, levetiracetam
Behavioral
abnormalities
involuntary midline
hand movements,
bruxism
involuntary midline
hand movements,
bruxism
involuntary midline
hand movements,
bruxism
no hyperactivity
Apparent hypertelorism
(HP:0000316)
yes yes yes yes yes
Upslanting palpebral
fissures (HP:0000582)
yes yes yes no no
Broad nasal bridge
(HP:0000431)
yes yes yes yes yes
Broad nasal tip yes yes yes yes yes
Short nose
(HP:0003196)
yes yes yes yes yes
Tented upper-lip
vermilion
(HP:0010804)
yes yes yes yes yes
Large, fleshy ear lobes
(HP:0009748)
yes yes yes no yes
Cleft palate
(HP:0000175)
yes yes no (high palate) no no
Brachytelephalangy
(HP:0009882)
no no no no no
Serum total ALP (U/l)
(HP:0003155)
739 1,407 1,452 926–2,000 928–1,370
Upper limit in ALP
test (U/l)
525–600 525–600 525–600 400 386
(Continued on next page)
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Table 1. Continued
Clinical Findingsa
Individual
V-1 (Family A) V-2 (Family A) V-3 (Family A) II-1 (Family B) II-1 (Family C)
Further anomalies no no no no thin corpus callosum,
dilated lateral ventricles
PGAP3 variants
(RefSeq NM_033419.3)
homozygous
c.275G>A
(p.Gly92Asp)
homozygous
c.275G>A
(p.Gly92Asp)
homozygous
c.275G>A
p.Gly92Asp)
compound-heterozygous
c.914A>G (p.Asp305Gly)
and c.439dupC
(p.Leu147Profs*16)
homozygous c.314C>G
(p.Pro105Arg)
Abbreviations are as follows: ALP, alkaline phosphatase; OFC, occipitofrontal circumference; and NA, not applicable.
aHuman phenotype ontology IDs are provided if applicable.wild-type and p.Gly92Asp PGAP3 were found mainly in
the Golgi and to a lesser extent in the ER (Figure 5, first
and second rows). Only faint bands were seen with
p.Leu147Profs*16 from family B, indicating that the level
of altered protein was not significant (Figure 4C). The other
family B substitution, p.Asp305Gly, showed a main bandThe Americat 35 kDa (Figure 4A, lane 6) that was shifted to the
33 kDa de-N-glycosylated full-size protein after treatment
with either PNGase F or Endo H, the latter of which elim-
inated only immature N-glycan (lanes 4 and 5). This profile
indicated that the p.Asp305Gly altered protein had only
immature ER-form N-glycan. Consistently, the alteredFigure 3. Flow Cytometric Analysis of
Granulocyte Surface GPI-APs and Flow
Cytometric Assay for Functions of Altered
PGAP3
(A)Bloodgranulocytes fromtheaffected in-
dividual in familyB (solid line)were stained
withanti-CD24andanti-CD16andfluores-
cence-labeled aerolysin (FLAER). The light-
gray area represents a healthy control.
(B) PGAP3 and PGAP2 double-mutant
CHO cells were transfected with PGAP3
cDNA and 2 days later were stained for
CD59, CD55 (DAF), and uPAR. (Bi) After
transfection with wild-type PGAP3 cDNA,
the surface levels of three GPI-APs were
severely reduced (solid lines). The dark
area shows the original surface levels of
GPI-APs on PGAP3 and PGAP2 double-
mutant CHO cells, whereas the light gray
area represents the isotype-matched con-
trol. (Bii) The PGAP3 cDNA bearing muta-
tion c.275G>A (p.Gly92Asp) in family A
either did not reduce or only slightly
reduced GPI-AP levels (solid lines). (Biii)
The PGAP3 cDNA bearing one mutation,
c.439dupC (p.Leu147Profs*16), in family
B did not reduce GPI-AP levels (solid lines),
whereas that bearing the other mutation,
c.914A>G (p.Asp305Gly), significantly
reduced GPI-AP levels, indicating a hypo-
morphic mutant phenotype (dotted lines).
(Biv) The PGAP3 cDNA bearing mutation
c.314C>G (p.Pro105Arg) in family C
slightly reduced the levels of three GPI-
APs, indicating a hypomorphic but very
severe loss-of-function phenotype (solid
lines).
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Figure 4. SDS-PAGE and Immunoblot-
ting of HA-Tagged PGAP3
(A) Lanes 1–3, wild-type; lanes 4–6,
p.Asp305Gly; lanes 7–9, p.Gly92Asp. Pro-
tein levels shown as quantity were normal-
ized with the intensities of GAPDH for the
loading control and luciferase activities for
the transfection efficiencies. The antibody
showed no reactivity in lysates from
empty-vector-transfected cells.
(B) Lanes 1–3, wild-type; lanes 4–6,
p.Pro105Arg.
(C) Lane 1, wild-type; lane 2,
p.Leu147Profs*16; lane 3, empty vector.
There are two N-glycosylation sites in
PGAP3. The mature PGAP3 appears as a
smear at 37–45 KDa (A, lane 3). This smear
is sensitive to PNGase F, suggesting hetero-
geneous N-glycans. Bands seen below the
35 KDa position represent degradation
products because they are not seen in the
empty-vector transfectant (C, lane 3) or
the transfectant with the truncated
p.Leu147Profs*16 protein (C, lane 2).
Abbreviations are as follows: N, no treat-
ment; P, PNGase F treatment; and E,
Endo H treatment.protein was found in the ER, but not the Golgi (Figure 5,
third row). Similarly, the p.Pro105Arg substitution in
family C generated only an immature protein with ER-
form N-glycan, as shown by a lack of a smear band at
around 37–45 kDa (Figure 4B, lane 6) and a shift of the
clear major band at 35 kDa to 33 kDa after Endo-H
treatment (lanes 5 and 6). Consistent with these results,
p.Pro105Arg PGAP3 was localized to the ER, but not to
the Golgi (Figure 5, fourth row).
Therefore, the four substitutions that we describe had
different effects on PGAP3, the Golgi-resident GPI-specific
phospholipase A2 consisting of an N-terminal luminal
domain, seven transmembrane domains with conserved
catalytic amino acids, and a C-terminal cytoplasmic tail
(Figure S4). (1) The p.Gly92Asp substitution did not affect
protein levels or Golgi localization, yet the altered protein
had only negligible activity. Because Gly92 resides in a
juxta membrane position on the luminal side, a negative
charge caused by this substitution might interfere with
the association between PGAP3 and GPI anchor substrate.
(2) The p.Leu147Profs*16 protein was not detected sig-
nificantly, consistent with nonsense-mediated mRNA
degradation. (3) The p.Asp305Gly and p.Pro105Arg pro-
teins were readily detectable but had immature N-glycan
and were mislocalized in the ER. Asp305 resides in the
cytoplasmic tail, whereas Pro105 resides in the first trans-
membrane domain. The cytoplasmic tail and the first
transmembrane domain might be important for Golgi
localization.
The characteristic biochemical phenotype of individuals
with PGAP3 deficiency is hyperphosphatasia, a sign of
GPI-AP release from the cell surface. However, the reduc-
tion of GPI-AP levels is expected to depend on the cell
type and species, as studies in Pgap3-knockout mice284 The American Journal of Human Genetics 94, 278–287, Februarysuggest.24,25 In fact, flow cytometric analysis from the
affected individual in family B demonstrated significant
reduction in the cell-surface levels of GPI-APs in blood
granulocytes (Figure 3A), whereas the CD59 surface levels
in erythrocytes of an affected individual in family A were
found to be normal. This confirms that GPI remodelling
by PGAP3 is not essential for CD59 surface levels in
erythrocytes, given that the GPI-anchor structure in eryth-
rocytes maintains an unsaturated fatty acid at the sn2
position.26
The exact mechanism of release has yet to be character-
ized, but GPI-APs bearing unremodelled fatty acids are not
associated well with lipid rafts.17 This abnormalmembrane
distribution might affect the stability of GPI-APs, resulting
in release from the cell surface. Although both PGAP3 and
PGAP2 are involved in fatty acid remodeling, the above
mechanism of hyperphosphatasia or GPI-AP release from
PGAP3-deficient cells is different from that observed in
PGAP2-deficient cells. In the latter cells, only the first
reaction by PGAP3, elimination of unsaturated fatty
acid, occurs and the resulting lyso-GPI intermediate is
cleaved and released by a putative lyso-GPI-specific phos-
pholipase D.15
In summary, we identified four different PGAP3 muta-
tions in three unrelated families by using two independent
strategies. In family A, recruited on account of postnatal
microcephaly, a combination of autozygosity mapping
and exome sequencing identified a missense variant in
PGAP3 as the only likely candidate. In families B and C,
mutations were uncovered in the same gene via a targeted
sequencing approach in a cohort of individuals ascertained
specifically for ID and hyperphosphatasia. In spite of
the different approaches, the convergent findings, taken
together with the segregation, the absence of these6, 2014
Figure 5. Subcellular Localization of
HA-Tagged PGAP3 in CHO Cells
(First row) Wild-type.
(Second row) p.Gly92Asp in family A.
(Third row) p.Asp305Gly in family B.
(Fourth row) Pro105Arg in family C.
GM-130 is the Golgi marker. The relatively
high levels of the ER form of HA-tagged
wild-type PGAP3 seen in the top panels
and also in lane 3 in Figure 4A might
have been due to overexpression.variants in suitable controls, phylogenetic conservation,
and functional studies on CHO cell lines, provide strong
evidence supporting the etiological role of these muta-
tions. Along with PGAP1 and PGAP2, PGAP3 is responsible
for the modification of the fatty acid residues on the GPI
anchor in a maturation process that occurs in the ER and
Golgi. Our results and previously reported data on PGAP2
mutations suggest that impairment of fatty acid remodel-
ling results in GPI-APs that are more prone to cleavage
on the plasma membrane and clinical features that are
similar to HPMRS. Our findings widen both the pheno-
typic and the genotypic spectra of hyperphosphatasia
and ID syndromes that are caused by mutations in PIGV,
PIGO, and PGAP2 and suggest a heterogeneous etiology
caused by impairment of late GPI-anchor synthesis and
the GPI-AP-maturation pathway. These functional muta-
tions define this condition as a CDG, PGAP3-CDG. In
contrast to classical CDGs, which affect N-glycosylation
and O-glycosylation, or both, defects in the GPI-anchor-
biosynthesis pathway cannot be detected with a trans-
ferrin or APOCIII glycosylation assay. This underlines the
importance of comprehensive genetic testing of individ-
uals with suspected CDGs.The AmericSupplemental Data
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